Difference between revisions of "Team:NUDT CHINA/Description"

(Prototype team page)
 
 
(20 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
{{NUDT_CHINA}}
 
{{NUDT_CHINA}}
<html>
+
<html lang="en">
 +
<head>
 +
    <meta charset="utf-8">
 +
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
 +
    <link rel="stylesheet" href="basic.css">
 +
    <style type="text/css">
 +
p {font-variant: stacked-fractions;
 +
font-size: large;}
 +
.pure-g p{font-variant: stacked-fractions;
 +
font-size: large;}
 +
.main-title{padding-top:50%; padding-bottom:50%;width:100%;}
 +
.main{width:90%;}
 +
.main-title::before {
 +
content: '';
 +
width: 20vw;
 +
height: 20vw;
 +
min-width: 3.5em;
 +
min-height: 3.5em;
 +
background: url(https://static.igem.org/mediawiki/2017/f/fe/T-NUDT_CHINA-BigTitle.svg) no-repeat center center;
 +
background-size: cover;
 +
position: absolute;
 +
top: 50%;
 +
left: 50%;
 +
border-radius: 50%;
 +
z-index: 3;
 +
-webkit-transform: translate3d(-50%,-50%,0);
 +
transform: translate3d(-50%,-50%,0);}
 +
.large-header {
 +
background-image: url('https://static.igem.org/mediawiki/2017/a/a5/T-NUDT_CHINA-bigheader-Description.jpg');}
  
 +
    </style>
 +
</head>
 +
 
 +
  <div id="layout">
 +
        <a href="#menu" id="menuLink" class="menu-link">
 +
            <span></span>
 +
        </a>
 +
        <div id="menu">
 +
        <div class="pure-menu"><img src="https://static.igem.org/mediawiki/2017/4/4f/T-NUDT_CHINA-icon01.png" width=240px height=190px alt="">
 +
          <ul class="pure-menu-list">
 +
            <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA" class="pure-menu-link">HOME</a></li>             
 +
         
 +
            <li class="pure-menu-item pure-menu-has-children">
 +
              <a  class="pure-menu-link"onclick="Show('team_show')">TEAM</a>
 +
              <ul class="pure-menu-children" id="team_show">
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Team" class="pure-menu-link">Team</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Collaborations" class="pure-menu-link">Collaborations</a></li>
 +
            </ul>
 +
            </li>
 +
            <li class="pure-menu-item pure-menu-has-children">
 +
              <a  class="pure-menu-link"onclick="Show('project_show')">PROJECT</a>
 +
              <ul class="pure-menu-children" id="project_show">
 +
                <li class="pure-menu-item"><a class="pure-menu-heading" href="https://2017.igem.org/Team:NUDT_CHINA/Description" class="pure-menu-link">Description</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Design" class="pure-menu-link">Design</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Experiments" class="pure-menu-link">Experiment</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Notebook" class="pure-menu-link">Notebook</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Results" class="pure-menu-link">Results</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Demonstrate" class="pure-menu-link">Demonstrate</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Improve" class="pure-menu-link">Improve</a></li>
 +
            </ul>
 +
            </li>
 +
            <li class="pure-menu-item pure-menu-has-children">
 +
              <a  class="pure-menu-link"onclick="Show('part_show')">PARTS</a>
 +
              <ul class="pure-menu-children" id="part_show">
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Parts" class="pure-menu-link">Parts</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Basic_Part" class="pure-menu-link">Basic Parts</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Composite_Part" class="pure-menu-link">Composite Parts</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Part_Collection" class="pure-menu-link">Part Collection</a></li>
 +
            </ul>
 +
            </li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Attributions" class="pure-menu-link">Attributions</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/InterLab" class="pure-menu-link">InterLab</a></li>
 +
                <li class="pure-menu-item"><a  href="https://2017.igem.org/Team:NUDT_CHINA/Model" class="pure-menu-link">Model</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Safety" class="pure-menu-link">SAFETY</a></li>
 +
            <li class="pure-menu-item pure-menu-has-children">
 +
              <a  class="pure-menu-link"onclick="Show('HP_show')">HP</a>
 +
              <ul class="pure-menu-children" id="HP_show">
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/HP/Silver" class="pure-menu-link">Silver HP</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/HP/Gold_Integrated" class="pure-menu-link">Integrated & Gold</a></li>
 +
                <li class="pure-menu-item"><a href="https://2017.igem.org/Team:NUDT_CHINA/Engagement" class="pure-menu-link">Public Engagement</a></li>
 +
            </ul>
 +
            </li>
 +
            </ul>
 +
        </div> 
 +
        </div>
 +
        <div id="main">
 +
        <div id="large-header" class="large-header">
 +
                    <canvas id="demo-canvas"></canvas>
 +
                    <h1 class="main-title">Description</span></h1>
 +
                </div>
 +
       
  
 +
        <div class="content" style="width: 74%">
 +
<style>
 +
.reference{margin-top: 100px;}
 +
.reference p{text-indent: 0;line-height: initial;
 +
    font-size: large;
 +
    font-family: monospace;}
 +
</style>
  
<div class="column full_size">
 
<h1>Description</h1>
 
  
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
+
<div class="Myheader">
 +
            <h5>Introduction</h5>
 +
        </div>
  
 +
<p>MicroRNAs (miRNAs) are small non-coding RNAs 18~24 nucleotides in length that have been proven to play important roles on post-transcriptional regulation of the gene expression<sup>1</sup>.&nbsp;Up to now, over 2000 miRNAs have been identified or predicted from human tissues or cells<sup>2</sup>. Mature miRNAs are&nbsp;mainly&nbsp;existing&nbsp;in&nbsp;cytoplasm and, together with Argonaute (Ago)&nbsp;family of protein,&nbsp;packed into a protein complex known as miRNA-induced silencing complex (RISC)<sup>3</sup>. Base-paring to 3&rsquo; untranslated region (3&rsquo; UTR)&nbsp;of target mRNA, miRNA would induce translational repression or mRNA degradation&nbsp;due to the&nbsp;endonucleolytic activity of Ago, thus regulating gene expression and participants in many pivotal biological processes (Figure 1, right panel), including cell proliferation, differentiation, migration and apoptosis<sup>4-6</sup>.&nbsp;To understand the regulatory mechanism of miRNA, miRNA gain of function and loss of function research are necessary. Thus, methods for inhibiting functional microRNAs <em>in vitro</em>&nbsp;and <em>in vivo</em>&nbsp;is wildly needed in miRNA researches<sup>7-9</sup>.</p>
 +
<center><img width="80%" src="https://static.igem.org/mediawiki/2017/f/f3/T-NUDT_CHINA-intro1.jpg" alt=""></center>
 +
<p style="font: caption; text-indent:0;"><strong>Figure 1.</strong> Schematic representation of our project. Left panel shows the assembly strategy of miRNA. Right panel shows the mechanism how miRNA Lockers inhibit target miRNA activity. </p>
 +
<p style="margin-top: 50px;">Presently, loss-of-function phenotypes are mainly&nbsp;induced by means of chemically modified antisense oligonucleotides(ASO). Chemically modified antisense oligonucleotides&nbsp;includes 2&rsquo;O-methyl, 2&rsquo;O-methoxyethyl, locked nucleic acid (LNA) and others, which aims to pair with and block mature microRNAs through strictly sequence complementarity<sup>10</sup>. Antagomirs are&nbsp;a group of chemically&nbsp;modified antisense&nbsp;oligonucleotides, which&nbsp;are&nbsp;readily available tools wildly&nbsp;used for endogenous&nbsp;miRNA inhibition<sup>3</sup>. To improve the stability and miRNA binding affinity, different&nbsp;modifications are introduced to&nbsp;antagomir&nbsp;and optimized to achieve&nbsp;high fidelity, low toxicity, and improved stability. Although there are many advantages of ASO, limited scalability and off-target effects still limit the extensive usage of ASO in miRNA loss of function study.</p>
 +
<p>Apart&nbsp;from&nbsp;ASO, two other approaches have been reported to be utilized in miRNA loss of function researches. One is called &ldquo;miRNA&nbsp;sponge&rdquo;, which stands for a class of competitive inhibitor of miRNA carrying multiple binding sites of miRNA<sup>11</sup>. Another is termed &ldquo;miRNA mask&rdquo;&nbsp;<sup>12</sup>, which use oligonucleotides to perfectly complementary to mRNA, like a mask covering miRNA binding sites. Therefore, miRNA cannot bind to mRNA and induce subsequently miRNA-mRNA interaction. However, miRNA inhibition using miRNA sponge or miRNA mask are not widely used for miRNA loss of function researches <sup>10</sup>.</p>
 +
<p>Notably, previous reports have demonstrated that miRNA can efficiently bind to single strand DNA in a base-matching manner. Deng et al. and our project last year also showed that non-modified DNA with dumb-bell-shaped secondary structure and miRNA binding sites on the loop region presents high miRNA binding affinity and improved stability<sup>13</sup>&nbsp;(see <a href="https://2016.igem.org/Team:NUDT_CHINA/Results"><u>https://2016.igem.org/Team:NUDT_CHINA/Results</u></a>&nbsp;). Hence, we anticipate dumb-bell-shaped DNA may serve as miRNA inhibitors as well.</p>
 +
<p>In our project, we demonstrated a dumb-bell-shaped DNA based design of miRNA inhibitor to achieve low-cost and&nbsp;high scalability with high inhibitory effect simultaneously. Our miRNA inhibitor, named as miRNA locker,&nbsp;can be easily assembled using modularized DNA parts from a set of chemically synthetic oligo DNA library (Figure 1, left panel).</p>
 +
<p>Using miR-214 as a demo of our scheme, we&nbsp;assembled miR-214 specific&nbsp;Locker&nbsp;based on our oligo DNA library and&nbsp;validate&nbsp;the function of Locker as&nbsp;miRNA&nbsp;inhibitor&nbsp;<em>in vitro</em>.&nbsp;To be specific, we <strong>demonstrated</strong><strong>&nbsp;that miRNA lockers could be efficiently recognized by ago-miRNA complex and further functioned by lowering the target miRNA level</strong>. <strong>Downstream</strong>&nbsp;<strong>gene expression changes and phenotypic changes</strong>&nbsp;consistent to commercialized miRNA inhibitors were also observed. Our results also showed a better inhibitory effect of miRNA Lockers comparing to the commercialized miRNA inhibitors. These results indicate that <strong>miRNA Locker might be a promising substitute miRNA inhibitor with similar or even stronger inhibitory effects comparing</strong><strong>&nbsp;to existing ones</strong>.&nbsp;Also, we demonstrated how miRNA Lockers can be used in miRNA researches as a promising substitute of current miRNA inhibitors by identifying a new RNF8-targeting miRNA and establish its regulatory relationship with epithelial&ndash;mesenchymal transition (EMT).</p>
 +
<p>With the unique advantage and potential on multi-targeting and convenience of miRNA Locker, we believe that our design might provide an alternative approach for miRNA inhibiting for research, diagnostic and therapeutic uses.</p>
  
<h5>What should this page contain?</h5>
+
<div class="reference">
<ul>
+
<p style=" font-size: x-large; font-weight:bold;">References</p>
<li> A clear and concise description of your project.</li>
+
<p>1 Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. <em><em>Cell</em></em>&nbsp;<strong><strong>116</strong></strong>, 281-297 (2004).</p>
<li>A detailed explanation of why your team chose to work on this particular project.</li>
+
<p>2 Li, Y.<em><em>&nbsp;et al.</em></em>&nbsp;miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. <em><em>Molecules</em></em>&nbsp;<strong><strong>19</strong></strong>, 7122-7137, doi:10.3390/molecules19067122 (2014).</p>
<li>References and sources to document your research.</li>
+
<p>3 Sun, W., Julie Li, Y. S., Huang, H. D., Shyy, J. Y. &amp; Chien, S. microRNA: a master regulator of cellular processes for bioengineering systems. <em><em>Annual review of biomedical engineering</em></em>&nbsp;<strong><strong>12</strong></strong>, 1-27, doi:10.1146/annurev-bioeng-070909-105314 (2010).</p>
<li>Use illustrations and other visual resources to explain your project.</li>
+
<p>4 Esquela-Kerscher, A. &amp; Slack, F. J. Oncomirs - microRNAs with a role in cancer. <em><em>Nature reviews. Cancer</em></em>&nbsp;<strong><strong>6</strong></strong>, 259-269, doi:10.1038/nrc1840 (2006).</p>
</ul>
+
<p>5 Cui, Q., Yu, Z., Purisima, E. O. &amp; Wang, E. Principles of microRNA regulation of a human cellular signaling network. <em><em>Molecular systems biology</em></em>&nbsp;<strong><strong>2</strong></strong>, 46, doi:10.1038/msb4100089 (2006).</p>
 
+
<p>6 Cummins, J. M. &amp; Velculescu, V. E. Implications of micro-RNA profiling for cancer diagnosis. <em><em>Oncogene</em></em>&nbsp;<strong><strong>25</strong></strong>, 6220-6227, doi:10.1038/sj.onc.1209914 (2006).</p>
 +
<p>7 Watts, L. M.<em><em>&nbsp;et al.</em></em>&nbsp;Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. <em><em>Diabetes</em></em>&nbsp;<strong><strong>54</strong></strong>, 1846-1853 (2005).</p>
 +
<p>8 Zellweger, T.<em><em>&nbsp;et al.</em></em>&nbsp;Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. <em><em>The Journal of pharmacology and experimental therapeutics</em></em>&nbsp;<strong><strong>298</strong></strong>, 934-940 (2001).</p>
 +
<p>9 Yu, X. X.<em><em>&nbsp;et al.</em></em>&nbsp;Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. <em><em>Hepatology</em></em>&nbsp;<strong><strong>42</strong></strong>, 362-371, doi:10.1002/hep.20783 (2005).</p>
 +
<p>10 Meng, L.<em><em>&nbsp;et al.</em></em>&nbsp;Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. <em><em>Nature communications</em></em>&nbsp;<strong><strong>8</strong></strong>, 13964, doi:10.1038/ncomms13964 (2017).</p>
 +
<p>11 Ebert, M. S., Neilson, J. R. &amp; Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. <em><em>Nature methods</em></em>&nbsp;<strong><strong>4</strong></strong>, 721-726, doi:10.1038/nmeth1079 (2007).</p>
 +
<p>12 Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. <em><em>Methods in molecular biology</em></em>&nbsp;<strong><strong>676</strong></strong>, 43-49, doi:10.1007/978-1-60761-863-8_3 (2011).</p>
 +
<p>13 Deng, R.<em>&nbsp;et al.</em>&nbsp;Toehold-initiated rolling circle amplification for visualizing individual microRNAs in situ in single cells. <em>Angew Chem Int Ed Engl</em>&nbsp;<strong>53</strong>, 2389-2393, doi:10.1002/anie.201309388 (2014).</p>
 +
</div>
  
 +
 
 
</div>
 
</div>
 +
</div></div>
  
<div class="column full_size" >
+
<script type="text/javascript">
 +
function send(num) {
 +
  var openClass = 'is-open';
 +
var add1=document.getElementById(num);
 +
var add2=document.getElementById('Lay'+num);
 +
addClass(add1,openClass);
 +
addClass(add2,openClass);
 +
function hasClass(element,csName){
 +
      return  element.className.match(RegExp('(\\s|^)'+csName+'(\\s|$)'));
 +
    };
 +
function addClass(element,csName){
 +
       if(!hasClass(element,csName)){
 +
 +
         element.className+=' '+csName;
 +
 +
      }
 +
};}
 +
function show(num) {
 +
var openClass = 'is-open';
 +
var remove1=document.getElementById(num);
 +
var remove2=document.getElementById('Lay'+num);
 +
deleteClass(remove1,openClass);
 +
deleteClass(remove2,openClass);
 +
function hasClass(element,csName){
 +
      return  element.className.match(RegExp('(\\s|^)'+csName+'(\\s|$)'));
 +
    };
 +
  function deleteClass(element,csName){   
 +
if (hasClass(element,csName)) {
 +
        var reg = new RegExp("(\\s|^)" + csName + "(\\s|$)");
 +
        element.className = element.className.replace(reg, " ");
 +
    }
 +
};
 +
}
  
<h5>Advice on writing your Project Description</h5>
+
</script>
 +
<script type="text/javascript">
 +
( function(window,document){
  
<p>
+
    var layout  = document.getElementById('layout'),
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.  
+
        menu    = document.getElementById('menu'),
</p>
+
        menuLink = document.getElementById('menuLink'),
 +
        content  = document.getElementById('main');
  
<p>
+
    function toggleClass(element, className) {
Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.
+
        var classes = element.className.split(/\s+/),
</p>
+
            length = classes.length,
 +
            i = 0;
  
</div>
+
        for(; i < length; i++) {
 +
          if (classes[i] === className) {
 +
            classes.splice(i, 1);
 +
            break;
 +
          }
 +
        }
 +
        // The className is not found
 +
        if (length === classes.length) {
 +
            classes.push(className);
 +
        }
  
 +
        element.className = classes.join(' ');
 +
    }
  
<div class="column half_size" >
+
    function toggleAll(e) {
 +
        var active = 'active';
  
<h5>References</h5>
+
        e.preventDefault();
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
+
        toggleClass(layout, active);
 +
        toggleClass(menu, active);
 +
        toggleClass(menuLink, active);
 +
    }
  
</div>
+
    menuLink.onclick = function (e) {
 +
        toggleAll(e);
 +
    };
  
 +
    content.onclick = function(e) {
 +
        if (menu.className.indexOf('active') !== -1) {
 +
            toggleAll(e);
 +
        }
 +
    };
  
<div class="column half_size" >
+
}(this, this.document));
<h5>Inspiration</h5>
+
</script>
<p>See how other teams have described and presented their projects: </p>
+
  
<ul>
+
<script type="text/javascript" >
<li><a href="https://2016.igem.org/Team:Imperial_College/Description">2016 Imperial College</a></li>
+
    function Show(tagId) {
<li><a href="https://2016.igem.org/Team:Wageningen_UR/Description">2016 Wageningen UR</a></li>
+
    if (document.getElementById(tagId).style.display=="none") {
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> 2014 UC Davis</a></li>
+
    document.getElementById(tagId).style.display="block";
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">2014 SYSU Software</a></li>
+
   
</ul>
+
    }
</div>
+
    else {
 +
    document.getElementById(tagId).style.display="none";
 +
    }
 +
    }
 +
</script>
 +
<script type="text/javascript" >
 +
(function() {
 +
 
 +
    var width, height, largeHeader, canvas, ctx, circles, target, animateHeader = true;
 +
 
 +
    // Main
 +
    initHeader();
 +
    addListeners();
 +
 
 +
    function initHeader() {
 +
        width = window.innerWidth;
 +
        height = window.innerHeight;
 +
        target = {x: 0, y: height};
 +
 
 +
        largeHeader = document.getElementById('large-header');
 +
        largeHeader.style.height = height+'px';
 +
 
 +
        canvas = document.getElementById('demo-canvas');
 +
        canvas.width = width;
 +
        canvas.height = height;
 +
        ctx = canvas.getContext('2d');
 +
 
 +
        // create particles
 +
        circles = [];
 +
        for(var x = 0; x < width*0.5; x++) {
 +
            var c = new Circle();
 +
            circles.push(c);
 +
        }
 +
        animate();
 +
    }
 +
 
 +
    // Event handling
 +
    function addListeners() {
 +
        window.addEventListener('scroll', scrollCheck);
 +
        window.addEventListener('resize', resize);
 +
    }
 +
 
 +
    function scrollCheck() {
 +
        if(document.body.scrollTop > height) animateHeader = false;
 +
        else animateHeader = true;
 +
    }
 +
 
 +
    function resize() {
 +
        width = window.innerWidth;
 +
        height = window.innerHeight;
 +
        largeHeader.style.height = height+'px';
 +
        canvas.width = width;
 +
        canvas.height = height;
 +
    }
 +
 
 +
    function animate() {
 +
        if(animateHeader) {
 +
            ctx.clearRect(0,0,width,height);
 +
            for(var i in circles) {
 +
                circles[i].draw();
 +
            }
 +
        }
 +
        requestAnimationFrame(animate);
 +
    }
 +
 
 +
    // Canvas manipulation
 +
    function Circle() {
 +
        var _this = this;
 +
 
 +
        // constructor
 +
        (function() {
 +
            _this.pos = {};
 +
            init();
 +
            console.log(_this);
 +
        })();
  
 +
        function init() {
 +
            _this.pos.x = Math.random()*width;
 +
            _this.pos.y = height+Math.random()*100;
 +
            _this.alpha = 0.1+Math.random()*0.3;
 +
            _this.scale = 0.1+Math.random()*0.3;
 +
            _this.velocity = Math.random();
 +
        }
  
 +
        this.draw = function() {
 +
            if(_this.alpha <= 0) {
 +
                init();
 +
            }
 +
            _this.pos.y -= _this.velocity;
 +
            _this.alpha -= 0.0005;
 +
            ctx.beginPath();
 +
            ctx.arc(_this.pos.x, _this.pos.y, _this.scale*10, 0, 2 * Math.PI, false);
 +
            ctx.fillStyle = 'rgba(255,255,255,'+ _this.alpha+')';
 +
            ctx.fill();
 +
        };
 +
    }
  
 +
})();
 +
</script>
 +
</body>
 
</html>
 
</html>

Latest revision as of 00:06, 2 November 2017

Description

Introduction

MicroRNAs (miRNAs) are small non-coding RNAs 18~24 nucleotides in length that have been proven to play important roles on post-transcriptional regulation of the gene expression1. Up to now, over 2000 miRNAs have been identified or predicted from human tissues or cells2. Mature miRNAs are mainly existing in cytoplasm and, together with Argonaute (Ago) family of protein, packed into a protein complex known as miRNA-induced silencing complex (RISC)3. Base-paring to 3’ untranslated region (3’ UTR) of target mRNA, miRNA would induce translational repression or mRNA degradation due to the endonucleolytic activity of Ago, thus regulating gene expression and participants in many pivotal biological processes (Figure 1, right panel), including cell proliferation, differentiation, migration and apoptosis4-6. To understand the regulatory mechanism of miRNA, miRNA gain of function and loss of function research are necessary. Thus, methods for inhibiting functional microRNAs in vitro and in vivo is wildly needed in miRNA researches7-9.

Figure 1. Schematic representation of our project. Left panel shows the assembly strategy of miRNA. Right panel shows the mechanism how miRNA Lockers inhibit target miRNA activity.

Presently, loss-of-function phenotypes are mainly induced by means of chemically modified antisense oligonucleotides(ASO). Chemically modified antisense oligonucleotides includes 2’O-methyl, 2’O-methoxyethyl, locked nucleic acid (LNA) and others, which aims to pair with and block mature microRNAs through strictly sequence complementarity10. Antagomirs are a group of chemically modified antisense oligonucleotides, which are readily available tools wildly used for endogenous miRNA inhibition3. To improve the stability and miRNA binding affinity, different modifications are introduced to antagomir and optimized to achieve high fidelity, low toxicity, and improved stability. Although there are many advantages of ASO, limited scalability and off-target effects still limit the extensive usage of ASO in miRNA loss of function study.

Apart from ASO, two other approaches have been reported to be utilized in miRNA loss of function researches. One is called “miRNA sponge”, which stands for a class of competitive inhibitor of miRNA carrying multiple binding sites of miRNA11. Another is termed “miRNA mask” 12, which use oligonucleotides to perfectly complementary to mRNA, like a mask covering miRNA binding sites. Therefore, miRNA cannot bind to mRNA and induce subsequently miRNA-mRNA interaction. However, miRNA inhibition using miRNA sponge or miRNA mask are not widely used for miRNA loss of function researches 10.

Notably, previous reports have demonstrated that miRNA can efficiently bind to single strand DNA in a base-matching manner. Deng et al. and our project last year also showed that non-modified DNA with dumb-bell-shaped secondary structure and miRNA binding sites on the loop region presents high miRNA binding affinity and improved stability13 (see https://2016.igem.org/Team:NUDT_CHINA/Results ). Hence, we anticipate dumb-bell-shaped DNA may serve as miRNA inhibitors as well.

In our project, we demonstrated a dumb-bell-shaped DNA based design of miRNA inhibitor to achieve low-cost and high scalability with high inhibitory effect simultaneously. Our miRNA inhibitor, named as miRNA locker, can be easily assembled using modularized DNA parts from a set of chemically synthetic oligo DNA library (Figure 1, left panel).

Using miR-214 as a demo of our scheme, we assembled miR-214 specific Locker based on our oligo DNA library and validate the function of Locker as miRNA inhibitor in vitro. To be specific, we demonstrated that miRNA lockers could be efficiently recognized by ago-miRNA complex and further functioned by lowering the target miRNA level. Downstream gene expression changes and phenotypic changes consistent to commercialized miRNA inhibitors were also observed. Our results also showed a better inhibitory effect of miRNA Lockers comparing to the commercialized miRNA inhibitors. These results indicate that miRNA Locker might be a promising substitute miRNA inhibitor with similar or even stronger inhibitory effects comparing to existing ones. Also, we demonstrated how miRNA Lockers can be used in miRNA researches as a promising substitute of current miRNA inhibitors by identifying a new RNF8-targeting miRNA and establish its regulatory relationship with epithelial–mesenchymal transition (EMT).

With the unique advantage and potential on multi-targeting and convenience of miRNA Locker, we believe that our design might provide an alternative approach for miRNA inhibiting for research, diagnostic and therapeutic uses.

References

1 Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).

2 Li, Y. et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19, 7122-7137, doi:10.3390/molecules19067122 (2014).

3 Sun, W., Julie Li, Y. S., Huang, H. D., Shyy, J. Y. & Chien, S. microRNA: a master regulator of cellular processes for bioengineering systems. Annual review of biomedical engineering 12, 1-27, doi:10.1146/annurev-bioeng-070909-105314 (2010).

4 Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nature reviews. Cancer 6, 259-269, doi:10.1038/nrc1840 (2006).

5 Cui, Q., Yu, Z., Purisima, E. O. & Wang, E. Principles of microRNA regulation of a human cellular signaling network. Molecular systems biology 2, 46, doi:10.1038/msb4100089 (2006).

6 Cummins, J. M. & Velculescu, V. E. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25, 6220-6227, doi:10.1038/sj.onc.1209914 (2006).

7 Watts, L. M. et al. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846-1853 (2005).

8 Zellweger, T. et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. The Journal of pharmacology and experimental therapeutics 298, 934-940 (2001).

9 Yu, X. X. et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362-371, doi:10.1002/hep.20783 (2005).

10 Meng, L. et al. Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. Nature communications 8, 13964, doi:10.1038/ncomms13964 (2017).

11 Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature methods 4, 721-726, doi:10.1038/nmeth1079 (2007).

12 Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods in molecular biology 676, 43-49, doi:10.1007/978-1-60761-863-8_3 (2011).

13 Deng, R. et al. Toehold-initiated rolling circle amplification for visualizing individual microRNAs in situ in single cells. Angew Chem Int Ed Engl 53, 2389-2393, doi:10.1002/anie.201309388 (2014).